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Histamine-Induced Conjunctivitis and Breakdown of Blood–Tear Barrier
in Dogs: A Model for Ocular Pharmacology and Therapeutics
Abstract
Conjunctival inflammation disturbs the blood–tear barrier and thus affects the tear film stability and
composition. We aimed to develop a non-invasive and reliable method to induce conjunctivitis in dogs, a large
animal model for translational work on ocular surface disease in humans. Six beagle dogs underwent a
randomized, vehicle-controlled, balanced crossover trial—on six separate days, one eye received topical
artificial tears (vehicle), while the other eye received one of six concentrations of histamine solution
(0.005–500 mg/ml). At sequential times after eyedrop administration, a conjunctivitis score was given to each
eye based on the degree of palpebral and bulbar conjunctival hyperemia and chemosis, ocular pruritus, and
discharge. Total protein content (TPC) and serum albumin were quantified in tear fluid at baseline and 20
min. Additionally, 13 dogs presenting for various ophthalmic diseases with associated conjunctivitis were
examined. Experimentally induced conjunctivitis developed rapidly (<1 >min) following topical histamine
administration and lasted for 1–3 h (four lowest doses) to 6–8 h (two highest doses). The severity of
conjunctivitis was dose-dependent. Histamine was overall well tolerated, although transient blepharitis,
aqueous flare, and ocular hypertension occurred in a few dogs receiving histamine ≥375 mg/ml. TPC and
serum albumin levels increased in tears of eyes receiving histamine ≥1.0 mg/ml, being significantly higher
than vehicle and baseline in eyes receiving histamine ≥375 mg/ml. Lacrimal albumin levels were also
increased in 13 dogs with naturally acquired conjunctivitis, up 2.7–14.9 fold compared to contralateral healthy
eyes. Histamine-induced conjunctivitis represents a robust model for translational work on the ocular surface
given the low cost, non-invasiveness, self-resolving nature, ability to adjust the duration and severity of the
disease, and shared features with naturally occurring ocular diseases. Histamine solutions of 1, 10, and 375
mg/ml induce mild, moderate, and severe conjunctivitis in dogs, respectively. Leakage of serum albumin in
tear fluid of eyes with conjunctivitis suggests a breakdown of the blood–tear barrier.
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Conjunctival inflammation disturbs the blood–tear barrier and thus affects the tear film 
stability and composition. We aimed to develop a non-invasive and reliable method 
to induce conjunctivitis in dogs, a large animal model for translational work on ocular 
surface disease in humans. Six beagle dogs underwent a randomized, vehicle-controlled, 
balanced crossover trial—on six separate days, one eye received topical artificial tears 
(vehicle), while the other eye received one of six concentrations of histamine solution 
(0.005–500 mg/ml). At sequential times after eyedrop administration, a conjunctivitis 
score was given to each eye based on the degree of palpebral and bulbar conjunctival 
hyperemia and chemosis, ocular pruritus, and discharge. Total protein content (TPC) and 
serum albumin were quantified in tear fluid at baseline and 20 min. Additionally, 13 dogs 
presenting for various ophthalmic diseases with associated conjunctivitis were examined. 
Experimentally induced conjunctivitis developed rapidly (<1  min) following topical 
histamine administration and lasted for 1–3 h (four lowest doses) to 6–8 h (two highest 
doses). The severity of conjunctivitis was dose-dependent. Histamine was overall well 
tolerated, although transient blepharitis, aqueous flare, and ocular hypertension occurred 
in a few dogs receiving histamine ≥375 mg/ml. TPC and serum albumin levels increased 
in tears of eyes receiving histamine ≥1.0 mg/ml, being significantly higher than vehicle 
and baseline in eyes receiving histamine ≥375 mg/ml. Lacrimal albumin levels were also 
increased in 13 dogs with naturally acquired conjunctivitis, up 2.7–14.9 fold compared 
to contralateral healthy eyes. Histamine-induced conjunctivitis represents a robust model 
for translational work on the ocular surface given the low cost, non-invasiveness, self-
resolving nature, ability to adjust the duration and severity of the disease, and shared 
features with naturally  occurring ocular diseases. Histamine solutions of 1, 10, and 
375  mg/ml  induce  mild, moderate, and severe conjunctivitis in dogs, respectively. 
Leakage of serum albumin in tear fluid of eyes with conjunctivitis suggests a breakdown 
of the blood–tear barrier.
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INTRODUCTION
Conjunctivitis, or inflammation of the vascularized mucous 
membrane lining the inside of the eyelids, anterior sclera, 
and (when present) the nictitating membrane, is a common 
ocular surface disease in both humans and veterinary patients 
(Azari and Barney, 2013; Maggs, 2018). In addition to well-
recognized etiologies (e.g., infectious, allergic, toxic/irritative, 
immune-mediated), conjunctivitis frequently develops as 
a bystander to most adnexal and ocular diseases, such as 
blepharitis, keratitis, uveitis, and glaucoma (Azari and Barney, 
2013; Maggs, 2018). Regardless of the cause, conjunctivitis is 
debilitating to patients due to ocular discomfort, redness, and 
discharge, as well as the potential development of conjunctival 
scarring, fornix foreshortening, or symblepharon in severe or 
untreated cases. Further, conjunctivitis compromises the tear 
film homeostasis and thereby contributes indirectly to ocular 
surface damage. Changes in tear composition result from 
a loss of secretory function and numbers of mucin secreting 
goblet cells (Contreras-Ruiz et al., 2013), but can also be 
linked to the disruption of the blood–tear barrier—a critical 
yet poorly understood mechanism (van Delft et al., 1997). 
Indeed, conjunctivitis increases vascular permeability and 
results in leakage of plasma compounds into the tear film, as 
exemplified by human patients with conjunctivitis and dry eye 
who were noted to have significantly greater serum albumin 
in tears compared to healthy controls (Zavaro et al., 1980; van 
Bijsterveld and Janssen, 1981; Janssen and van Bijsterveld, 1986; 
Li et al., 2010), and dogs with spontaneous keratoconjunctivitis 
sicca for whom the clinical signs of conjunctivitis were 
positively correlated with tear levels of serum proteins (Fullard 
et al., 1995).
Despite the prevalence of conjunctivitis, there is limited 
knowledge about the disease impact on the ocular surface in 
clinical patients. Are tear film composition and quality affected 
by conjunctivitis-induced breakdown of the blood–tear barrier? 
Is there an impact on the pharmacokinetic profile of drugs on 
the ocular surface? Do medications administered systemically 
reach the tear film compartment at higher concentrations? Such 
knowledge can be gained from experimentally induced models 
of conjunctivitis in animals, such as intraperitoneal injection 
of ovalbumin in guinea pigs (Shii et al., 2010) and topical 
administration of dust mite allergens in dogs (Lourenço-
Martins et al., 2011). However, a delayed response occurs 
with ovalbumin (6  h from antigen exposure to conjunctival 
pathology), and dust mite allergens only cause conjunctivitis 
in individuals already sensitized to this antigen. In contrast, the 
use of topical histamine is promising as it causes conjunctivitis 
in a nonspecific and rapid manner (Takahashi et al., 2010) 
and the compound is a potent inflammatory mediator that is 
associated with various disorders such as allergy, inflammation, 
autoimmune conditions, and possibly cancer (Branco et al., 
2018). Takahashi and colleagues used topical histamine in 
guinea pigs and quantified the extravasation of Evans Blue 
to demonstrate vascular permeability in the conjunctiva 
(Takahashi et al., 2010). The authors focused on a single 
dose of histamine and did not assess the safety of the drug, 
disease severity, or disease duration. In the present study, the 
model of histamine-induced conjunctivitis was fine-tuned 
and perfected: we investigated a diverse range of histamine 
concentrations, performed serial ophthalmic and physical 
examinations to assess safety, and described in detail the 
clinical and biochemical changes observed at each dose. The 
dog is a preclinical species of choice for modeling human 
ocular diseases as the canine ocular anatomy is more similar 
to humans than routine laboratory species (Vézina, 2013); 
dogs share similar environmental stressors with people, and 
spontaneously occurring ocular surface diseases are common 
in this species. We are confident that this translatable in vivo 
model of conjunctivitis will guide future studies to gain a 
deeper understanding of the disease, elucidating the impact of 
conjunctivitis on drug pharmacokinetics, tear film dynamics, 
metabolomics, and proteomics, among others.
MATERIALS AND METHODS
Experimentally Induced Conjunctivitis 
in Dogs
Animals
Six beagle dogs (1.5–2.0 years, 7.7–10.1 kg) were used in 
the study. The gender and neuter status was the same for all 
subjects (female spayed), as sex hormones are known to be key 
regulators of vascular tone in various organs, including the eye 
(Schmidl et al., 2015). All dogs were confirmed to be healthy 
based on complete physical and ophthalmic examinations, 
including slit-lamp biomicroscopy (SL-17; Kowa Company, 
Ltd., Tokyo, Japan), indirect funduscopy (Keeler Vantage; Keeler 
Instruments, Inc., Broomall, PA, USA), rebound tonometry 
(TonoVet; Icare Finland Oy, Espoo, Finland), Schirmer tear 
test-1 (STT-1; Eye Care Product Manufacturing LLC, Tucson, 
AZ, USA), and fluorescein staining (Flu-Glo, Akorn, Inc., 
Buffalo Grove, IL, USA). The dogs were group-housed in 
kennels with ambient temperature maintained at 18–24°C and 
lights automatically turned on/off at 06:00/18:00. The study was 
approved by the Institutional Animal Care and Use Committee 
of Iowa State University (log # 2-18-8704-K) and adhered to 
the Association for Research in Vision and Ophthalmology 
(ARVO) statement for the Use of Animals in Ophthalmic and 
Vision Research.
Topical Histamine and Vehicle Solutions
Histamine ophthalmic solutions were formulated by mixing 
histamine powder (Histamine dihydrochloride, FCC grade, 
Arcos® organics, Geel, Belgium) in 1.4% polyvinyl alcohol 
lubricating eye drops (Artificial tears solution, Rugby, Rockville 
Center, NY, USA) using a sterile manner under a laminar flow 
hood. The pH of each solution was tested with a pH meter (B-212 
Twin compact pH, Horiba, Kyoto, Japan) and adjusted to 6.5 by 
adding 1% sodium hydroxide (prepared from granules mixed 
with sterile water), one drop at a time until the target pH was 
reached. The following 12 concentrations of histamine solution 
were compounded into 15-ml sterile eyedropper bottles (Steri-
dropper®, Medi-Dose®, Ivyland, PA, USA) by the pharmacist at 
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Iowa State University’s Lloyd Veterinary Medical Center: 0.001, 
0.005, 0.01, 0.0375, 0.1, 0.5, 1.0, 10, 100, 375, 500, and 1,000 
mg/ml. The vehicle solution consisted of artificial tears solution 
adjusted to pH of 6.5 with a minute amount of 1% sodium 
hydroxide (< 5 drops in 15-ml bottle). Histamine and vehicle 
solutions were used within 24 h of preparation and kept in the 
dark at room temperature (18–24°C) before use and in between 
experiments.
Experimental Design
Pilot Study to Assess Tolerability and Appropriate Histamine 
Concentrations
A pilot study was conducted to assess the tolerability of histamine 
solutions in dogs (local and systemic) and the most appropriate 
concentrations to select for the crossover trial. Each of the 12 eyes 
(n = 6 dogs) was randomly allocated to one of the 12 histamine 
concentrations (Excel, Microsoft, Redmond, WA, USA). A 
single drop of histamine solution was instilled onto the ocular 
surface, followed by slit-lamp biomicroscopy and conjunctivitis 
scoring at 1, 3, 5, 7, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 180, 240, 
300, 360, and 420  min. Additionally, the following ocular and 
physical parameters were recorded at 1, 10, 20, 30, 60, 120, and 
240  min post-histamine administration: intraocular pressure, 
aqueous flare grading, body temperature, heart rate, respiratory 
rate, respiratory efforts, capillary refill time, and indirect blood 
pressure (Doppler model 811-B, Parks Medical Electronics, Las 
Vegas, NV, USA).
Balanced Crossover Vehicle-Controlled Trial
Six histamine solutions were selected for the crossover trial based 
on good tolerability and diversity of conjunctivitis scoring (pilot 
study, data not shown). The six histamine solutions are listed 
as follows: H1 = 0.005 mg/ml, H2 = 0.1 mg/ml, H3 = 1.0 mg/ml, 
H4 = 10 mg/ml, H5 = 375 mg/ml, and H6 = 500 mg/ml. For each 
dog, one eye received histamine solution (random selection by 
coin-toss) while the other eye received vehicle solution, and 
this order was kept consistent throughout the study. Each dog 
received all six histamine solutions over six consecutive days, 
using one solution per day (once in the morning) in a balanced 
crossover trial (Supplementary Figure 1). In each dog, ocular 
and physical parameters were recorded at selected times (similar 
to pilot study), while tear collection and conjunctivitis scoring 
were performed as outlined below:
• Tear collection: At baseline and at 20  min post-eyedrop 
administration, tear fluid was collected from both eyes and 
total protein content (TPC) was analyzed as previously 
described (Sebbag et al., 2018b). Briefly, a standardized 
Schirmer strip was inserted into the ventrolateral conjunctival 
fornix until the 20-mm mark was reached. Each wetted 
Schirmer strip was placed into a 0.2-ml tube (pre-punctured 
at its bottom with an 18-gauge needle), secured into a 2-ml 
tube with adhesive tape, and centrifuged at 3,884 × g for 
2  min (Mini Centrifuge, VWR International, Radnor, PA, 
USA). After estimating the volume of extracted tear fluid with 
a pipette, each tear sample was diluted 1:3 with phosphate-
buffered saline (PBS 1X, Gibco™, Thermo Fisher Scientific, 
Inc., Waltham, WA, USA). TPC was calculated with Direct 
Detect™ infrared spectrometer and expressed in mg/ml 
after adjusting for the threefold dilution of each sample. 
Subsequently, the residual tear fluid was diluted fourfold with 
diluent provided with the albumin ELISA kit (Serum albumin 
ELISA kit, Life Span Biosciences, Inc., Seattle, WA, USA). 
Serum albumin and various cytokines/chemokines/growth 
factors (Canine Procarta Plex™ 11-plex immunoassay, Cat 
No EPX11A-50511-901, Thermo Fischer Scientific, Waltham, 
MA, USA) were quantified in each tear sample following the 
manufacturer’s protocol.
• Conjunctivitis score: At baseline and at selected times post-
eyedrop administration (similar to pilot study), one examiner 
(LS) who was masked to which eye received histamine or 
vehicle solution performed slit-lamp biomicroscopy of both 
eyes to determine a conjunctivitis score at each time point. 
The conjunctivitis score was calculated as the sum of the 
following categories, each graded on a three- to four-point scale 
(Supplementary Table 1): hyperemia, chemosis and follicles of 
the palpebral and bulbar conjunctiva, conjunctival discharge, 
and ocular pruritus (Uchio et al., 2008; Eaton et al., 2017).
Naturally Acquired Conjunctivitis in Dogs
Thirteen dogs presenting to Iowa State University’s Lloyd 
Veterinary Medical Center (ISU-LVMC) for clinical ophthalmic 
disease with associated conjunctivitis were enrolled. A verbal 
informed consent was obtained from all owners, which was 
sufficient for the hospital’s ethics committee given that Schirmer 
tear test is part of routine clinical care. Dogs were examined 
by a board-certified veterinary ophthalmologist (LS or RA) for 
diagnosis and treatment of various ocular complaints including 
corneal ulceration, uveitis, and glaucoma. Details of the dogs 
(breed, sex, age) and their clinical diagnosis are presented in 
Table 1. Tear collection and albumin analysis were performed in 
both eyes of each dog as described above.
Data Analysis
Normality of the data was assessed with the Shapiro–Wilk 
test. The one-way ANOVA and Tukey post hoc test was used to 
compare the six histamine doses for i) duration of conjunctivitis, 
determined as the time for conjunctivitis score to return to 
zero, and ii) severity of conjunctivitis, determined by the area 
under the curve of conjunctivitis score from 0 to 180  min. 
Within each histamine dose, the one-way repeated measures 
ANOVA and Bonferroni post hoc test was used to assess 
differences in conjunctivitis scores between time points. The 
Student t-test was used to evaluate differences between vehicle 
and histamine-treated eyes for TPC and albumin levels, both 
at baseline and at 20  min following eyedrop administration. 
Further, a ratio was calculated for TPC and albumin levels 
for each histamine dose as follows: (Concentration histamine 
20 min/histamine baseline)/(Concentration vehicle 20 min/
vehicle baseline). This ratio describes the percentage change in 
protein levels between baseline and 20 min post-induction of 
conjunctivitis, taking into account the variability inherent to 
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the tear collection method itself by adding the vehicle-treated 
eyes as the denominator (Sebbag et al., 2018b). The one-way 
ANOVA and Tukey post hoc test was used to assess differences 
in protein ratios and levels of cytokines/chemokines/growth 
factors in tears of different groups. In dogs with naturally 
acquired conjunctivitis, differences in lacrimal concentrations 
of albumin between affected and unaffected eyes were 
analyzed with the Mann–Whitney test. Statistical analysis 
was performed using SigmaPlot version 14.0 (Systat Software, 
Point Richmond, CA), and values P < 0.05 were considered 
statistically significant.
RESULTS
Experimentally Induced Conjunctivitis 
in Dogs
Clinical Features of Conjunctivitis
All eyes receiving the vehicle solution were scored at zero for 
all time points. In eyes receiving histamine, the ocular surface 
was examined from different angles to evaluate the canine 
conjunctiva in a comprehensive manner, including a view from 
the front (Figure 1A), side (Figure 1B), top (Figure 1C), and 
globe retropulsion with lower lid retraction (Figure 1D), which 
facilitated assessment of the palpebral conjunctiva and nictitating 
membrane. Figure 2 shows representative photographs and 
conjunctivitis scoring of a canine eye at 30  min following H4 
administration (10 mg/ml histamine solution), while Figure 3 
demonstrates the development and progression of conjunctivitis 
from 0 to 420  min in a canine eye receiving H5 (375 mg/ml 
histamine solution). Data were normally distributed such that 
results are presented as mean ± standard deviation (range).
Conjunctivitis developed rapidly (<1  min) for all doses 
(Figure 4A). Of note, not a single eye developed conjunctival 
follicles. Details of conjunctivitis scoring for each subsection 
(palpebral chemosis, bulbar hyperemia, etc.) is described in 
Supplementary Table 2.
The duration of conjunctivitis was statistically different among 
histamine doses (P < 0.001), ranging from 61 ± 37 min (25–120 
min) for H1, 110 ± 36 min (90–180 min) for H2, 115 ± 52 min 
(60–180 min) for H3, 190 ± 45 min (120–240 min) for H4, 390 ± 
33 min (360–420 min) for H5, and 400 ± 31 min (360–420 min) 
for H6. All pairwise comparisons were statistically significant 
(P ≤ 0.029) except for H1–H3 (P = 0.201) and H5–H6 (P = 0.998).
The severity of conjunctivitis was significantly different 
among histamine doses (P < 0.001), with an AUC0–180min (in score x 
min) ranging from 59.2 ± 36.8 (21.5–119) for H1, 200.2  ± 53.9 
(107.5–254.5) for H2, 277.2 ± 128.3 (144.5–495.5) for H3, 522.3 ± 
131.8 (358–735) for H4, 1,168.5 ± 266.4 (892.5–1,585) for H5, and 
1,186.5 ± 242.4 (914–1,443.5) for H6. All pairwise comparisons 
were statistically significant (P ≤ 0.037) except for H5–H6 
(P = 1.000) and H2–H3 (P = 0.794; Figure 4B).
A post hoc power analysis showed that n = 5 dogs were 
sufficient to detect a difference in total clinical scores of 2.2 (as 
observed clinically in eyes with mild vs. moderate vs. severe 
conjunctivitis), a standard deviation of 0.9, a power of 80%, and 
an α value of 0.05.
Tolerance
Locally, histamine administration was very well tolerated in 
dogs except for transient adverse effects noted with H5 and 
H6: i) Blepharitis, manifested by mild blepharedema and 
erythema (Figure 5A), was noted in 1/6 dogs receiving H5 
and 2/6 dogs receiving H6, developing within 10–30 min of 
FIGURE 2 | Photographs of the left eye in a dog, 30 min following topical 
administration of 10 mg/ml histamine solution. The overall conjunctivitis score 
was 6, based on the absence/presence and degree of follicles, hyperemia, 
and chemosis of both palpebral and bulbar conjunctiva, conjunctival 
discharge, and ocular pruritus.
FIGURE 1 | A comprehensive evaluation of the canine conjunctiva is 
facilitated by examination of the ocular surface at different angles, including a 
front view (A), side view (B), top view (C), and globe retropulsion with lower 
lid retraction (D). The latter permits visualization of the palpebral conjunctiva 
and nictitating membrane.
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histamine administration and self-resolving within 3  h. ii) 
Aqueous flare, subtle in intensity (trace to 1+), was noted in 
2/6 dogs receiving H5 and 6/6 dogs receiving H6, developing 
within 25–90 min and self-resolving within 1–3 h. Aqueous 
flare was commonly accompanied by miosis (Figure  5B). 
iii) Ocular hypertension, defined as IOP > 25 mmHg 
(Sebbag et al., 2018b), was noted in 1/6 dogs receiving H5 at 
30  min (IOP = 32 mmHg), although it was not statistically 
greater than baseline IOP (P = 0.529) and it self-resolved 
within 10  min. Ocular hypertension was also noted in 3/6 
dogs receiving H6 in which IOP was significantly higher at 
30 min (23.8 ± 5.5 mmHg; P = 0.011) and 60 min (23.2 ± 2.6 
mmHg; P = 0.029) compared to baseline (16.8 ± 2.6 mmHg). 
FIGURE 3 | Development and progression of conjunctivitis in a representative canine eye receiving topical 375 mg/ml histamine solution. Conjunctivitis developed 
rapidly (< 1 min), with progression of conjunctival hyperemia and chemosis for 20–30 min, and subsequent slow improvement and self-resolution by 420 min.
FIGURE 4 | (A) Graphs depicting the mean + SD of conjunctivitis score over time in dogs receiving H1 (0.005 mg/ml; white circles), H2 (0.1 mg/ml; black circles), 
H3 (1.0 mg/ml; white triangles), H4 (10 mg/ml; black triangles), H5 (375 mg/ml; white squares), and H6 (500 mg/ml; black squares). Within the same dose, a 
blue asterisk (*) depicts statistical significance of conjunctivitis scoring compared to baseline (for readability, only the first and last significant time points are 
depicted). (B) Box-and-whiskers plots depicting the area under the curve of conjunctivitis score from 0 to 180 min in dogs receiving topical histamine of various 
concentrations. Mean and median values are shown by horizontal dotted and solid lines, respectively. First and third quartiles (25th and 75th percentiles) are 
represented by the lower and upper limits of the box, respectively, while the 2.5th and the 97.5th percentiles are shown as the lower and upper whiskers, 
respectively. The conjunctivitis severity of histamine doses with different letters differ significantly (P < 0.05).
FIGURE 5 | Blepharitis (A) and miosis (B) in a dog that received high dose of 
histamine ophthalmic solution (500 mg/ml).
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FIGURE 6 | Bar charts depicting the total protein content (A, B) and serum albumin levels (C, D) in tears of six beagle dogs receiving vehicle or histamine eyedrops. 
An asterisk (*) indicates statistical significance (P < 0.05) between vehicle and histamine (A, C) or among histamine doses (B, D).
Importantly, no fluorescein stain uptake or corneal changes 
were noted for any histamine dose.
Systemically, all the vital parameters monitored were stable 
and not a single dog receiving H1 to H6 developed systolic 
hypotension (<90 mmHg). However, the systolic blood pressure 
dropped from 130 to 88 mmHg in a single dog receiving 1,000 
mg/ml histamine during the pilot phase, and the dog exhibited 
transient depression and weakness until blood pressure returned 
to baseline 10 min later.
Total Protein Content and Serum Albumin Levels 
in Tears
At baseline, lacrimal TPC varied from 3.0 to 29.0 mg/ml 
(8.8  ± 4.0 mg/ml) and no differences were noted between 
vehicle and histamine-treated eyes for any dose (P ≥ 0.365). 
Twenty minutes following eyedrop administration, lacrimal 
TPC varied from 2.3 to 36.3 mg/ml (9.9 ± 5.6 mg/ml) and was 
statistically greater in histamine vs. vehicle-treated eyes for H5 
(P = 0.009) and H6 (P = 0.021) but no other doses (P ≥ 0.310, 
Figure 6A). Mean ± SD (range) changes in TPC were 171 ± 
112% (6–271%) and 170 ± 181% (13–499%) for H5 and H6, 
respectively, values that were significantly greater than H1 and 
H2 (P ≤ 0.036, Figure 6B).
At baseline, albumin levels in tears varied from 0.015 to 
1.431 mg/ml (0.413 ± 0.455 mg/ml) and no differences were 
noted between vehicle and histamine eyes for any dose (P ≥ 
0.394). Twenty minutes following eyedrop administration, 
albumin levels varied from 0.019 to 9.595 mg/ml (1.158 ± 
2.098 mg/ml) and were statistically greater in histamine vs. 
vehicle-treated eyes for H5 (P = 0.021) and H6 (P = 0.029) but 
no other doses (P ≥ 0.106; Figure 6C). Mean ± SD (range) 
changes in albumin levels were 2,348 ± 1,454% (314–4,348%) 
and 4,031 ± 4,679% (583–12,689%) for H5 and H6, respectively, 
values that were significantly greater than H1 and H2 (P ≤ 
0.016; Figure 6D).
Canine Chemokines/Cytokines/Growth Factors 
in Tears
The levels of interferon-gamma (IFNγ), interleukin-2 (IL-2), 
and beta nerve growth factor (NGF-β) were below limits 
of quantification in all tear samples. Tear concentrations of 
other chemokines/cytokines/growth factors, described as 
mean ± standard deviation (range), were as follows (Figure 7): 
4.5 ± 19.4 pg/ml (0–147.6 pg/ml) for interleukin-6 (IL-6), 
2,647.8 ± 5,680.4 pg/ml (0–25,640.2 pg/ml) for interleukin-8 
(IL-8), 17.8 ± 16.3 pg/ml (0–86.8 pg/ml) for interleuekin-10 
(IL-10), 30.6 ± 104.0 pg/ml (0–807.3 pg/ml) for interleukin-12 
(IL-12), 532.5 ± 510.6 pg/ml (0–2,650.8 pg/ml) for vascular 
endothelial growth factor A (VEGF A), 0.80 ± 2.9 pg/ml 
(0–20.9 pg/ml) for tumor necrosis factor alpha (TNFα), 1.3 
± 4.3 pg/ml (0–24.8 pg/ml) for stem cell factor (SCF), and 
5.4 ± 13.1 pg/ml (0–80.2 pg/ml) for chemokine monocyte 
chemoattractant protein-1 (MCP-1). Statistical differences 
among groups (vehicle histamine solutions) were noted for 
IL-8 (Figure 7B), IL-10 (Figure 7C), IL-12 (Figure 7D), and 
VEGF A (Figure 7E).
Naturally Acquired Conjunctivitis in Dogs
Ocular disease was unilateral in all dogs, and spontaneous 
conjunctivitis was noted upon examination of all affected eyes 
(Figures 8–10). Lacrimal concentrations of albumin ranged from 
1.1 to 17.95 mg/ml in affected eyes, representing a significant 
change by 2.67–14.86 fold (P < 0.001) compared to lacrimal 
concentrations noted in contralateral unaffected eyes (0.13–3.06 
mg/ml). Re-examination of two dogs following therapy of the 
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FIGURE 7 | Bar charts depicting mean + SD of various chemokines, cytokines and growth factors quantified in tears of six beagle dogs receiving vehicle (vehicle) 
or histamine solutions: interleukin-6 (IL-6; A), interleukin-8 (IL-8; B), interleukin-10 (IL-10; C), interleukin-12 (IL-12; D), vascular endothelial growth factor A (VEGF A; 
E), tumor necrosis factor alpha (TNFα; F), stem cell factor (SCF; 1.3 ± 4.3 pg/ml; G), and chemokine monocyte chemoattractant protein-1 (MCP-1; H). Differences 
among groups are depicted by an asterisk (*) if statistically significant (P < 0.05).
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FIGURE 10 | Clinical photographs of a 5-year-old male castrated Pitbull 
(A, B) diagnosed with a spontaneous chronic corneal epithelial defect 
(case #12) and a 4-year-old female spayed Beagle (C, D) diagnosed with 
uveitis secondary to blastomycosis (case #13). Following treatment of each 
ocular disease (B, D), the severity of conjunctivitis was reduced and the 
concentration of albumin in tears was lower compared to the initial visit (A, C).
underlying ocular disease (cases #12–13; Table 1, Figure 10) 
showed reduction in lacrimal albumin concentrations concomitant 
with a reduction in the conjunctivitis score (Table 1).
DISCUSSION
The present study establishes a robust in vivo model of conjunctivitis 
in dogs, a translational large animal model that provides a 
framework for ocular surface studies in clinically relevant subjects, 
investigating the impact on conjunctivitis on tear film dynamics, 
pharmacokinetics, metabolomics, and other relevant fields. Dogs 
are an ideal large animal species for such translational model: not 
only does the canine ocular anatomy better resemble humans than 
small laboratory animals do (Vézina, 2013), but dogs also share 
similar environmental stressors to humans and conjunctivitis is a 
common and naturally occurring disease in this species (Maggs, 
2018). As a proof of concept, our study examined 13 dogs with 
naturally acquired conjunctivitis and confirmed the presence 
of elevated albumin levels in tears of affected eyes. Similar to 
histamine-induced conjunctivitis, eyes with naturally occurring 
disease exhibited a breakdown of the blood–tear barrier regardless 
of the underlying etiology (e.g., corneal ulceration, uveitis, 
glaucoma, and orbital cellulitis). Of note, the “blood–tear barrier” 
is not as well defined as other ocular barriers (e.g., blood–aqueous 
and blood–retinal barriers) and would benefit from future 
anatomical and physiological studies to confirm the terminology 
used in the present study and in previous work (Zavaro et al., 1980; 
van Bijsterveld and Janssen, 1981; Janssen and van Bijsterveld, 
1986; van Delft et al., 1997; Runstrom et al., 2013).
Histamine-induced conjunctivitis is not novel. The ocular use of 
histamine has been described in humans, guinea pigs, and rabbits 
FIGURE 9 | Clinical photographs of a 7-year-old female intact Coonhound 
dog (A) diagnosed with end-stage glaucoma in the right eye (case #11). Tear 
concentrations of albumin were much higher in the affected right eye (B) 
compared to the contralateral healthy left eye (C).
FIGURE 8 | Clinical photographs of canine eyes from patients presented to 
the Ophthalmology Service at Iowa State University’s Lloyd Veterinary Medical 
Center. Conjunctivitis is present in all eyes, a condition noted concurrently to 
various ocular diseases. Patient case numbers are listed in the top left corner 
of each photograph (see Table 1 for additional patient information).
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as the compound is inexpensive and triggers local inflammation in 
a non-specific manner (Hagedoorn and Maas, 1956; Bonini et al., 
1992; Takahashi et al., 2010). In dogs, we showed that histamine-
induced conjunctivitis is non-invasive, self-resolving, and dose-
dependent, allowing investigators to modulate the severity and 
duration of conjunctival inflammation by adjusting the dose of 
histamine solution administered. In fact, both parameters increased 
with histamine concentration until saturation in dose response 
observed at 375 mg/ml. Thus, we propose doses of 1, 10, and 375 
mg/ml to induce a mild, moderate, or severe conjunctivitis in dogs, 
respectively (Figure 11). Of note, histamine is not only associated 
with ocular allergies but also implicated in general inflammation, 
autoimmune conditions, and possibly cancer (Branco et al., 2018). 
Ocular allergy was not the scope of the present study, as many 
models and detailed descriptions of the condition already exist 
(Bundoc and Keane-Myers, 2003; Lourenço-Martins et al., 2011).
The model presented herein provides a unique opportunity for 
scientists to investigate the ocular surface in health and disease. First, 
since topical histamine had no impact on the contralateral eye, the 
model is applicable for studies that compare efficacy between drug 
TABLE 1 | Patient information and tear albumin concentrations in the affected and unaffected eyes of dogs presented to the Ophthalmology service at Iowa State 
University’s Lloyd Veterinary Medical Center with various ocular diseases.
Case # Patient 
information
Ocular disease Conjunctivitis score 
(affected eye/
unaffected eye)
Tear albumin 
concentration in 
affected eye (mg/ml)
Tear albumin 
concentration in 
unaffected eye (mg/ml)
Ratio affected 
vs.
unaffected eye
1 9 yo FS Yorkshire 
terrier
Keratoconjunctivitis 
sicca
4/0 3.50 1.22 2.87
2 9 yo MC French 
Bulldog
Corneal ulcer 
(superficial), Eyelid mass
6/1 2.44 0.80 3.05
3 4 yo MC Shih Tzu Corneal ulcer 
(superficial), Distichia
3/1 1.10 0.38 2.89
4 6 yo MC English 
Bulldog
Spontaneous chronic 
corneal epithelial defect
8/0 9.98 1.67 5.99
5 12 yo FS Shih Tzu Corneal ulcer (stromal) 5/0 3.51 0.84 4.18
6 12 yo FS English 
Springer Spaniel
Cataract,
Lens-induced uveitis
5/1 3.51 0.94 3.72
7 3 yo MC Border 
Collie
Uveitis (blastomycosis) 7/0 13.96 3.06 4.57
8 12 yo FS mixed 
breed
Uveitis,
Glaucoma (secondary)
5/0 1.80 0.24 7.52
9 4 yo MC Japanese 
Chin
Glaucoma (primary) 6/1 1.82 0.68 2.67
10 8 yo FS Beagle Orbital cellulitis 5/0 1.93 0.13 14.86
11 7 yo FI Coonhound Glaucoma (primary),
end-stage
6/0 17.95 1.72 10.42
12* 5 yo MC Pitbull Spontaneous chronic 
corneal epithelial defect
7/1
1/1 
6.30
1.74
1.77
1.74
3.55
1.0
13* 4 yo FS Beagle Uveitis (blastomycosis) 6/0
2/0 
1.52
0.37
0.42
0.34
3.60
1.09
*Cases 12 and 13 were examined twice: findings at the initial visit are shown in the first row, while findings following treatment of the ocular disease are depicted in the second row. 
yo, year old; FS, female spayed; MC, male castrated; FI, female intact.
FIGURE 11 | Representative clinical pictures of mild conjunctivitis (A; score = 3), moderate conjunctivitis (B; score = 6), and severe conjunctivitis (C; score = 9) following 
topical administration of histamine in dogs.
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and placebo, allowing for precise measurements of a drug action 
given the rapid (1 min) and sustained (120–420 min) development 
of conjunctivitis. Second, the changes noted in tear fluid levels of 
TPC and albumin strongly suggest a breakdown of the blood–tear 
barrier. In particular, albumin represents a marker of vascular 
permeability and plasma leakage given it is not produced by the 
lacrimal gland or corneo-conjunctival tissue (Runstrom et al., 2013). 
Our findings are consistent with previous reports of conjunctivitis, 
whether experimentally induced or naturally occurring from dry 
eye (van Delft et al., 1997), corneal ulcers, allergies, or others (de 
Freitas Campos et al., 2008; Runstrom et al., 2013). The mechanism 
of histamine-induced disruption of the blood–tear barrier is 
unknown. Increased vascular permeability likely plays a role 
(Ashton and Cunha-Vaz, 1965; van Bijsterveld and Janssen, 1981; 
Takahashi et al., 2010), combined with a disruption of tight junctions 
between conjunctival epithelial cells due to increased contractility 
of actin linked to these adhesion complexes (Guo et al., 2007). The 
breakdown of the blood–tear barrier could be exploited for assessing 
the impact of conjunctivitis on drug pharmacokinetics, tear film 
metabolomics, and other fields. In the field of pharmacology, for 
instance, the vast majority of studies to date are limited to healthy 
subjects with intact blood–tear barriers (Hirosawa et al., 2015; Sebbag 
et al., 2018a; Sebbag et al., 2018b; Sebbag et al., 2018c), in whom the 
lacrimal drug concentrations likely under-estimate the ones noted in 
actual clinical patients with ocular surface inflammation (Grumetto 
et al., 2002). Such discrepancies likely result in inappropriate dosing, 
thus affecting the drug efficacy and increasing the risk of toxicity or 
antimicrobial resistance (Craig, 1998).
In addition to protein quantification, the present study 
investigated a panel of cytokines/chemokines/growth factors 
in tear samples of dogs. Similar to human subjects with ocular 
surface disease such as dry eye or vernal keratoconjunctivitis 
(Leonardi et al., 2009; Enríquez-de-Salamanca et al., 2010), an 
increase in VEGF A, pro-inflammatory cytokines (IL-8, IL-12), 
and anti-inflammatory cytokine (IL-10) was detected in tears 
of dogs with experimentally induced conjunctivitis. Analysis of 
other biomarkers such as acidic mammalian chitinase (Bucolo 
et al., 2008; Musumeci et al., 2008) would be beneficial in future 
studies, but the paucity of tear fluid collected in each dog limited 
the number of compounds that could be analyzed.
The relatively low number of dogs enrolled in the histamine 
experiment is a clear limitation of our work, although a post hoc 
power analysis showed that n = 5 dogs were sufficient to detect 
significant differences between histamine doses for the main study 
outcome (clinical severity of conjunctivitis). Furthermore, although 
the subjectivity of our clinical scoring may be perceived as a 
drawback, given that photograph-based methods are mainstream in 
human studies (Schulze et al., 2007; Macchi et al., 2018), the method 
described herein is purposely adapted to working with dogs. Indeed, 
i) a handheld slit-lamp greatly facilitates examination of animals for 
whom the skull conformation and behavior traits are poorly suited 
for table-mounted devices (Eaton et al., 2017), and ii) the presence 
of the nictitating membrane and the minimal bulbar conjunctival 
exposure in dogs require a “dynamic” examination of the ocular 
surface that is not conducive to photographic scales. The ocular 
adverse effects noted with high doses of histamine represent another 
potential limitation of the proposed model. There was minimal to 
absent local irritation from all doses, likely favored by adjusting 
the test solutions to more physiologic pH values, but histamine 
concentrations ≥375 mg/ml resulted in meaningful side effects in 
selected cases. A transient breakdown of the blood–ocular barrier 
likely explains the anterior uveitis (Ashton and Cunha-Vaz, 1965), 
while ocular hypertension may be linked to the aforementioned acute 
uveitis and/or episcleral venous compression from the overlying 
swollen conjunctiva, causing an increased resistance to aqueous 
outflow (Allbaugh et al., 2011; Carreon et al., 2017). Future studies 
are required to characterize these adverse effects in detail. Lastly, the 
study does not explain the mechanistic reason of breakdown of the 
blood–tear barrier, as we mainly focused on documenting the safety 
and clinical features of the model in dogs. Our group is now working 
on characterizing the biochemical and histological changes resulting 
from histamine-induced conjunctivitis in dogs.
In summary, histamine-induced conjunctivitis in dogs 
represents a robust and reliable model for translational research 
on the ocular surface. The model is particularly appealing given 
the low cost, non-invasiveness, self-resolving nature, ability to 
adjust the duration and severity of the disease, and shared features 
with naturally occurring diseases in human and veterinary 
medicine. The model could be used to assess new therapeutics 
and to better understand the impact of conjunctivitis on drug 
pharmacokinetics–pharmacodynamics, tear film dynamics, and 
tear film composition, among many other applications.
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